Tristel PLC

LSE TSTL.L

Tristel PLC Shareholders' Equity for the year ending June 30, 2024: USD 41.02 M

Tristel PLC Shareholders' Equity is USD 41.02 M for the year ending June 30, 2024, a 5.35% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Tristel PLC Shareholders' Equity for the year ending June 30, 2023 was USD 38.94 M, a 10.36% change year over year.
Tristel PLC Shareholders' Equity for the year ending June 30, 2022 was USD 35.28 M, a -15.16% change year over year.
Tristel PLC Shareholders' Equity for the year ending June 30, 2021 was USD 41.59 M, a 17.87% change year over year.
Tristel PLC Shareholders' Equity for the year ending June 30, 2020 was USD 35.28 M, a 19.02% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

LSE: TSTL.L

Tristel PLC

CEO	Mr. Matthew G. Sassone
IPO Date	June 1, 2005
Location	United Kingdom
Headquarters	Lynx Business Park
Employees	250
Sector	Health Care
Industries Pharmaceuticals

Description

Tristel plc develops, manufactures, and sells infection prevention products in the United Kingdom and internationally. The company operates through three segments: Hospital Medical Device Decontamination, Hospital Environmental Surface Disinfection, and Other. It offers medical instrument disinfection products, including airway management, cardiology, ear, nose and throat, endoscopy, gastrointestinal physiology, laboratory, ophthalmology, phlebotomy, reproductive health/IVF, surface, ultrasound, urology, women's health, and other products under the Tristel brand. Tristel plc was founded in 1993 and is headquartered in Snailwell, the United Kingdom.

Key trends

Past 5 years